BC Extra | Dec 3, 2019
Clinical News

Biogen plotting next steps in lupus after latest readout

As Biogen seeks to build its immunology franchise, it became the latest company to post encouraging data in lupus, with BIIB059 meeting the primary endpoints in a Phase II trial to treat both cutaneous lupus...
BC Innovations | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

The lupus community gets its first break in a long while with three products showing efficacy in late-stage trials for systemic lupus erythematosis. That is welcome news in a disease that saw seven compounds fail...
BC Extra | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

A trio of companies reported positive data from late-stage systemic lupus erythematosis trials, raising hopes that new treatments are on the horizon for an indication that has seen only one new therapy approved in the...
BC Extra | Nov 11, 2019
Clinical News

DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most...
BC Extra | Aug 29, 2019
Clinical News

New lupus endpoint key to Phase III success for AZ’s anifrolumab

AstraZeneca's positive data for anifrolumab is the first successful Phase III trial in lupus in about a decade. But a previous Phase III failure for the mAb on a different endpoint leaves the pharma unable...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 7, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
BC Extra | Aug 31, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
Items per page:
1 - 10 of 26